Jounce Gets $47M Series A, Seeks to Jolt Cancer Therapy
Third Rock Ventures LLC plumbed its considerable network and assembled a team of prestigious cancer biologists and immunotherapy experts to form Jounce Therapeutics Inc., which launched Thursday with a $47 million Series A financing.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter